BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The discovery of imatinib (Gleevec)—the drug targeting the kinase domain of the BCR-ABL fusion (BCR gene from chromosome 9 and ABL gene of chromosome 22) has revolutionized the management of chronic myeloid leukemia by significantly improving patient’s survival.